



The AIDS Clinical Trials Group (ACTG) Network is the largest HIV/AIDS clinical trials organization in the world. We currently have 34 domestic & 25 international sites.



A5345 Highlighted in BETA HIV Remission Blog

A screenshot of the BETA HIV Remission Blog homepage. At the top left is a logo featuring a lightbulb with a red ribbon inside. To its right is the word 'BETA' in large, bold, black letters, followed by the tagline 'SWITCH ON YOUR HIV SMARTS.' Below this is a dark navigation bar with white text for 'HOME', 'NEWSWORTHY', 'LIVING WELL', 'TREATMENT', 'PREVENTION', and 'GAY MEN'S HEALTH'. The main content area features a featured article with a blue-tinted image of a virus particle. The article title is 'HOW DO WE KNOW IF SOMEONE'S IN HIV REMISSION?' and the byline is 'August 25, 2017, by Emily Newman'. The article text reads: 'AIDS Clinical Trials Group Network is conducting new research to learn how to predict when people with HIV can control their viral loads without HIV medications. Find out how you can get involved. [Read More](#) >'.

HOME **NEWSWORTHY** **LIVING WELL** **TREATMENT** **PREVENTION** **GAY MEN'S HEALTH**

 **HOW DO WE KNOW IF SOMEONE'S IN HIV REMISSION?**
August 25, 2017, by Emily Newman
AIDS Clinical Trials Group Network is conducting new research to learn how to predict when people with HIV can control their viral loads without HIV medications. Find out how you can get involved. [Read More](#) >

Protocol A5345: Biomarkers to Predict Time to Plasma HIV RNA Rebound Featured in Blog Post about HIV Remission

Earlier this month, A5345 was included in a blog posted on BETA discussing the latest updates in the field of HIV Remission. The article quoted Dr. Jonathan Li, A5345 Co-Principal Investigator, Brigham and Women's Hospital Clinical Research Site, who noted the importance of establishing biomarkers that can predict when HIV will become detectable in the blood after someone pauses HIV therapy. Currently, no test exists that can predict when a viral rebound will occur after pausing HIV therapy and it is unknown why some individuals rebound quickly while others remain suppressed for an extended period of time. Without the knowledge of when and why a person with HIV experiences a viral rebound after pausing treatment, it is challenging to develop strategies for achieving long-term HIV remission. To learn more about A5345 and read this blog post, [click here](#).

Outreach Recruitment & Retention Group Notes National HIV/AIDS Aging Awareness Day

An Estimated 3.6 Million People Over Age 50 are Living with HIV

National HIV/AIDS and Aging Awareness Day was launched by The AIDS Institute in an effort to raise awareness due to the alarming increase in the number of older adults becoming infected with HIV as well as those older adults over 50 aging with HIV. Every year, National HIV/AIDS and Aging Awareness Day (NHAAD) is observed on September 18th to highlight the complex issues related to HIV prevention, care and treatment for aging populations in the United States.



The ACTG Network's Outreach, Recruitment and Retention (OR&R) Working Group has collected a few resources to help Sites commemorate National HIV/AIDS and Aging Awareness Day. These are available for all ACTG sites, including those located outside of the United States. To learn more about how to take part in NHAAD, [click here](#).

To download a flyer that can be personalized for each site, [click here](#).

REPRIEVE Trial Hits Major Enrollment Milestone



REPRIEVE

**Over 4,000 Study Participants have Enrolled in the
REPRIEVE Trial**

In its third year of enrollment, the REPRIEVE Trial started August, 2017 with over 4,000 participants enrolled, a major milestone for this international trial striving to prevent cardiovascular disease in people living with HIV. With a total enrollment goal of 6,500, the REPRIEVE trial is expected to hit 75% of enrollment by October, 2017. In the past six months, enrollment has been augmented considerably thanks to the activation of several new international sites in South Africa, Botswana, Brazil, and India. Additionally, frequent enrollment competitions, where sites compete to enroll the most participants, can be credited for continuous recruitment enthusiasm and efforts.

Participant retention is also a very important goal in REPRIEVE. While each site has unique ways of keeping participants engaged, the REPRIEVE Trial recently hosted a REPRIEVE Forum in Washington, DC in June. This educational engagement event included dinner and presentations on cardiovascular disease prevention for REPRIEVE participants and others interested in the trial. Due to the success of this event, the trial plans to hold additional REPRIEVE Forum events in other US cities later this year.

"We are so pleased that REPRIEVE has enrolled over 4,000 participants and we are so grateful for the huge effort by so many people all over the world to help us reach this important milestone. With so much enthusiasm for REPRIEVE we are definitely looking forward to enrolling the last 2,500 participants within the next year," said Dr. Steven Grinspoon, REPRIEVE Principal Investigator, Massachusetts General Hospital Clinical Research Site.

Applications Open to International Researchers for Statistical & Data Analysis Center Internships

Internship Offers Unique Opportunity for International Researchers to Work with SDAC Statisticians and Epidemiologists

The ACTG will support up to two researchers from its international sites to receive internships to attend the Statistical and Data Analysis Center (SDAC) at the Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health (HSPH). The selected researcher(s) will collaborate on ACTG research projects and gain experience in the use of quantitative methods for the design and analysis of studies related to HIV/AIDS and its complications and co-infections. The emphasis will be on developing quantitative skills through the conduct of analyses on ACTG studies, ideally including one proposed by the researcher, as well as involvement in the development of statistical and data management aspects of ACTG studies. This includes the chance to attend seminars and courses focused on quantitative methods at SDAC and HSPH.

Top candidates are typically recent graduates or clinical fellows with a solid foundation and interest in bio-statistics and epidemiology. Interns are provided a supportive learning environment and have the opportunity to work directly with SDAC leadership.

The deadline for applications is Friday, September 15, 2017.

For more information about the SDAC Internship and application process, [click here](#).

Annual "A Day with HIV" is September 22, 2017

Consider Taking Part in "A Day with HIV" Campaign to Help Overcome Stigma Associated with HIV



Since 2012, ACTG Network clinicians, staff, and study participants have taken part in Positively Aware magazine's "A Day with HIV" campaign. The goal of "A Day with HIV" is to overcome stigma, and its message is simple: Everyone is affected by HIV and we can do something about it.

Although individuals with HIV are now living typical life-spans due to medical advances, there still is the need to show how we all live with HIV. Next month, on Friday, September 22, get out your camera or smart phone and capture a moment of your day.

Established in 2010, "A Day with HIV" is an anti-stigma picture-taking campaign open to everyone, everywhere, regardless of HIV status. To be considered for publication, upload your photo and caption to www.adaywithhiv.com or email it to photo@adaywithhiv.com.

If you have questions about "A Day with HIV" or the submission process, [click here](#).

This Year in HIV/AIDS History: 1996

February: The number of new AIDS cases diagnosed in the U.S. declines for the first time since the beginning of the epidemic.

May: U.S. Congress reauthorizes the Ryan White CARE Act.

July: 11th International AIDS Conference in Vancouver highlights the effectiveness of highly active antiretroviral therapy (HAART), creating a period of optimism.

October: The AIDS Memorial Quilt is displayed in its entirety for the last time. It covers the entire National Mall in Washington, DC.

December: HIV/AIDS researcher Dr. David Ho advocates for a new strategy for treating HIV - "hit early, hit hard," in which patients are placed on new, more aggressive treatment regimes earlier in the course of their infection in hopes of keeping them healthier longer. He is subsequently named TIME Magazine's "Man of the Year."

Source: AIDS.gov



Thank you for taking the time to read the ACTG Network's Monthly Newsletter. If you would like to be a guest blogger, have your clinical research site highlighted or would like to nominate a colleague for the Spotlight, please [click here](#). We welcome your feedback.


Sincerely,

Patrick Bayhille

Senior Research Communications Specialist

AIDS Clinical Trials Group Network

VISIT OUR WEBSITE

 Like us on Facebook  Follow us on **twitter**

Copyright © 2017. All Rights Reserved.

AIDS Clinical Trial Group (ACTG) Network,
900 Commonwealth Avenue, Boston, MA 02115